Tim Shea | Director
Sterne Kessler Goldstein And Fox Plc

Tim Shea, Director, Sterne Kessler Goldstein And Fox Plc

Mr. Shea is a director in the Biotechnology/Chemical Practice Group at Sterne, Kessler, Goldstein & Fox P.L.L.C., where he has practiced for 20 years.  He specializes in advising biopharmaceutical companies and research institutions on complex legal issues relating to the protection, enforcement and transfer of their intellectual property.  He practices primarily in the fields of immunology, molecular biology, genetic and medical diagnostics, biotherapeutics, and drug delivery.  He has extensive experience advising clients on the creation and management of strategic patent portfolios, freedom-to-operate and patentability issues, complex prosecution strategies, validity and infringement issues, and due diligence investigations in connection with acquisitions and investments.  Mr. Shea has published and spoken extensively on IP issues related to therapeutic antibodies and biosimilars.   In addition, a significant portion of his practice involves counseling emerging companies on strategies for creating, protecting and leveraging their IP assets to grow their businesses.

Mr. Shea received his B.S. in Biology from Washington and Lee University in 1988 and his J.D. from Chicago-Kent College of Law (with High Honors, Order of the Coif) in 1995. During law school, Mr. Shea served as an Executive Editor of the Law Review.  He then served as a judicial extern to the Honorable Rebecca Pallmeyer of the U.S. District Court for the Northern District of Illinois.  

Prior to attending law school, Mr. Shea worked for several years in the biotech industry in the areas of genetic diagnostics.


Biosimilars Day 2 - Wednesday 1st November 2017 @ 15:00

A year to review: 2017, more decisions, more launches, more unanswered questions

  • Hear how the year has played out from a legal perspective
  • What are we seeing from the US in terms of new decisions, new launches and their analysis of the data being submitted?
  • Incorporating IPRs into biosimilar litigation strategies
  • What impact is that having on the global biosimilar sector?

Biosimilars Day 2 - Wednesday 1st November 2017 @ 15:25

Panel: Legal and IP strategies to strengthen biosimilar medicine developers

  • How Brexit will impact the IP landscape and business strategies for the sector
  • A competitiveness boost: what are the opportunities for biosimilar medicine developers?
  • Establishing sustainability for second medical use patents
  • How to take advantage of the IP and regulatory environments to grow the generic and value added medicines business
  • Antitrust case law and latest developments
  • Inconsistencies in the SPC case law

back to speakers